Journal of Medicinal Chemistry · 2009 · 76 citations · 49 references
Life SciencesMedicinal ChemistryPharmacologyDrug DiscoverySteroid BiochemistryStructure-activity RelationshipsEnzyme InhibitionHormone ReceptorsHormone StructureLigand BindingSteroid Metabolism17 Beta-hydroxysteroid Dehydrogenases17-Beta Hydroxysteroid DehydrogenaseChemical SubstituentsFluorine ChemistryInhibitor PerformanceSelective Catalytic ReductionSelectivitySteroid Hormone Biosynthesis Inhibition
17beta-Hydroxysteroid dehydrogenase type 1 (17beta-HSD1) is responsible for the catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen receptor alpha (ERalpha). Because of the overexpression of 17beta-HSD1 in mammary tumors, this enzyme should be an attractive target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17beta-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes, and benzenes. In this paper, different substituents are introduced into the core structure and the biological properties of the corresponding inhibitors are evaluated. Computational methods and analysis of different X-rays of 17beta-HSD1 lead to identification of two different binding modes for these inhibitors. The fluorine compound 23 exhibits an IC(50) of 8 nM and is the most potent nonsteroidal inhibitor described so far. It also shows a high selectivity (17beta-HSD2, ERalpha) and excellent pharmacokinetic properties after peroral application to rats.
49
Helen M. Berman · Nucleic Acids Research · 2000 · 39.8K citations
Rapid colorimetric assay for cell growth and survival
François Denizot, Rita Lang · Journal of Immunological Methods · 1986 · 4.9K citations